Association between Insulin Resistance and Cardiovascular Risk Factors in Polycystic Ovary Syndrome Patients

Abstract

Objective To analyze the association between the indirect methods of evaluating insulin resistance (IR) and blood pressure, anthropometric and biochemical parameters in a population of polycystic ovary syndrome (PCOS) patients.

Methods Cross-sectional study performed at the Hospital Universitário de Brasília (HUB, in the Portuguese acronym) involving PCOS patients diagnosed from January 2011 to January 2013. Four indirect methods, namely, fasting blood insulin level, fasting glucose/insulin ratio (G/I), homeostatic model-assessment-insulin resistance (HOMA-IR), and the quantitative insulin sensitivity check index (QUICKI), were used to obtain the IR diagnosis. The data were analyzed using the test of proportions, the Chi-square test, and Fisher exact test, when indicated.

Results Out of the 83 patients assessed, aged 28.79 ± 5.85, IR was found in 51.81–66.2% of them using the G/I ratio and the QUICKI, respectively. The test of proportions did not show a significant difference between the methods analyzed. The proportion of IR diagnoses was statistically higher in obese women than in women with normal body mass index (BMI). We observed a statistically significant association between all the methods for diagnosing IR and BMI, waist circumference (WC) and lipid accumulation product (LAP). With regards to arterial hypertension (AH), we observed a significant association according to three methods, with the exception of the ratio G/I.

Conclusion Insulin resistance prevalence varied according to the diagnostic method employed, with no statistical difference between them. The proportion of IR diagnoses was statistically higher in obese women than in women with normal BMI. We observed a significant association between IR and WC, BMI, LAP, as well as dyslipidemia and AH in a high proportion of patients.

Resumo

Objetivo Analisar a associação entre os métodos indiretos de avaliação de resistência à insulina (RI) e parâmetros pressóricos, antropométricos e bioquímicos em uma população de pacientes com síndrome dos ovários policísticos (SOP).

Métodos Estudo transversal realizado no Hospital Universitário de Brasília (HUB), envolvendo pacientes que apresentaram o diagnóstico de SOP no período de janeiro de 2011 a janeiro de 2013. O diagnóstico de RI foi obtido por meio de quatro métodos indiretos: insulinemia de jejum, relação glicemia de jejum/insulinemia de jejum (G/I), avaliação da resistência à insulina através do modelo homeostático (HOMA-IR) e índice quantitativo de sensibilidade à insulina (QUICKI). Os dados foram analisados utilizando o teste de proporções, o teste do Qui-quadrado e o teste exato de Fisher, quando indicado.

Resultados Foram avaliadas 83 pacientes com idade média de 28,79 ± 5,85 anos. A RI foi diagnosticada em 51,81–66,27% dos casos pela relação G/I e QUICKI, respectivamente, e o teste de proporções não evidenciou diferença significativa entre os métodos analisados. A proporção de diagnósticos de RI foi estatisticamente maior em mulheres obesas em comparação à proporção de mulheres com índice de massa corporal (IMC) normal. Foi observada uma associação estatisticamente significativa entre todos os métodos diagnósticos de RI e IMC, circunferência da cintura (CC) e produto de acumulação lipídica (LAP). Quanto à hipertensão arterial (HA), foi observada associação significativa de acordo com três métodos, com exceção da relação G/I.

Conclusão A prevalência de RI variou conforme o método diagnóstico utilizado, mas não houve diferença estatística entre eles. A proporção de diagnósticos de IR foi maior nas mulheres obesas do que naquelas com peso normal. Foi observada associação significativa entre RI e CC, IMC e LAP, assim como com dislipidemia e HA em uma proporção elevada de pacientes.

Keywords

polycystic ovary syndrome - insulin resistance - body mass index - waist circumference - lipid accumulation product

Palavras-Chave

síndrome de ovários policísticos - resistência à insulina - índice de massa corporal - circunferência da cintura - produto de acumulação lipídica

Contributors

Wanderley M. S., Pereira L. C. R., Santos C. B., Cunha V. S. and Neves M. V. J. contributed with project and interpretation of data, writing of the article, critical review of the intellectual content and final approval of the version to be published.

• References

• 1 Baldani DP, Skrgatic L, Ougouag R. Polycystic ovary syndrome: important underrecognised cardiometabolic risk factor in reproductive-age women. Int J Endocrinol 2015; 2015: 786362
• 2 Laganà AS, Rossetti P, Buscema M. , et al. Metabolism and ovarian function in PCOS women: a therapeutic approach with inositols. Int J Endocrinol 2016; 2016: 6306410
• 3 Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev 2012; 33 (06) 981-1030 . Doi: 10.1210/er.2011-1034
• 4 Ramezani Tehrani F, Montazeri SA, Hosseinpanah F. , et al. Trend of cardio-metabolic risk factors in polycystic ovary syndrome: a population-based prospective cohort study. PLoS One 2015; 10 (09) e0137609 . Doi: 10.1371/journal.pone.0137609
• 5 Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19 (01) 41-47 . Doi: 10.1093/humrep/deh098
• 6 De Leo V, Musacchio MC, Cappelli V, Massaro MG, Morgante G, Petraglia F. Genetic, hormonal and metabolic aspects of PCOS: an update. Reprod Biol Endocrinol 2016; 14 (01) 38 . Doi: 10.1186/s12958-016-0173-x
• 7 Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961; 21: 1440-1447 . Doi: 10.1210/jcem-21-11-1440
• 8 World Health Organization. Obesity: Preventing and Managing the Global Epidemic: Report of a WHO Consultation . Geneva: WHO; 1997
• 9 National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106 (25) 3143-3421
• 10 Kahn HS. The “lipid accumulation product” performs better than the body mass index for recognizing cardiovascular risk: a population-based comparison. BMC Cardiovasc Disord 2005; 5: 26 . Doi: 10.1186/1471-2261-5-26
• 11 Wiltgen D, Benedetto IG, Mastella LS, Spritzer PM. Lipid accumulation product index: a reliable marker of cardiovascular risk in polycystic ovary syndrome. Hum Reprod 2009; 24 (07) 1726-1731 . Doi: 10.1093/humrep/dep072
• 12 Carmina E, Lobo RA. Use of fasting blood to assess the prevalence of insulin resistance in women with polycystic ovary syndrome. Fertil Steril 2004; 82 (03) 661-665 . Doi: 10.1016/j.fertnstert.2004.01.041
• 13 Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28 (07) 412-419 . Doi: 10.1007/BF00280883
• 14 Geloneze B, Repetto EM, Geloneze SR, Tambascia MA, Ermetice MN. The threshold value for insulin resistance (HOMA-IR) in an admixtured population IR in the Brazilian Metabolic Syndrome Study. Diabetes Res Clin Pract 2006; 72 (02) 219-220 . Doi: 10.1016/j.diabres.2005.10.017
• 15 Ding T, Baio G, Hardiman PJ, Petersen I, Sammon C. Diagnosis and management of polycystic ovary syndrome in the UK (2004-2014): a retrospective cohort study. BMJ Open 2016; 6 (07) e012461 . Doi: 10.1136/bmjopen-2016-012461
• 16 Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med 2010; 8: 41 . Doi: 10.1186/1741-7015-8-41
• 17 Moran C, Arriaga M, Rodriguez G, Moran S. Obesity differentially affects phenotypes of polycystic ovary syndrome. Int J Endocrinol 2012; 2012: 317241
• 18 Reyes-Muñoz E, Ortega-González C, Martínez-Cruz N. , et al. Association of obesity and overweight with the prevalence of insulin resistance, pre-diabetes and clinical-biochemical characteristics among infertile Mexican women with polycystic ovary syndrome: a cross-sectional study. BMJ Open 2016; 6 (07) e012107 . Doi: 10.1136/bmjopen-2016-012107
• 19 Palomba S, Santagni S, Falbo A, La Sala GB. Complications and challenges associated with polycystic ovary syndrome: current perspectives. Int J Womens Health 2015; 7: 745-763 . Doi: 10.2147/IJWH.S70314
• 20 Holte J, Gennarelli G, Berne C, Bergh T, Lithell H. Elevated ambulatory day-time blood pressure in women with polycystic ovary syndrome: a sign of a pre-hypertensive state?. Hum Reprod 1996; 11 (01) 23-28 . Doi: 10.1093/oxfordjournals.humrep.a019028
• 21 Martins WdeP, Soares GM, Vieira CS, dos Reis RM, de Sá MF, Ferriani RA. [Cardiovascular risk markers in polycystic ovary syndrome in women with and without insulin resistance]. Rev Bras Ginecol Obstet 2009; 31 (03) 111-116 . Doi: 10.1590/S0100-72032009000300002
• 22 Slowińska-Srzednicka J, Zgliczyński S, Wierzbicki M. , et al. The role of hyperinsulinemia in the development of lipid disturbances in nonobese and obese women with the polycystic ovary syndrome. J Endocrinol Invest 1991; 14 (07) 569-575
• 23 Wild RA, Rizzo M, Clifton S, Carmina E. Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis. Fertil Steril 2011; 95 (03) 1073-9.e1 , 11
• 24 Bass KM, Newschaffer CJ, Klag MJ, Bush TL. Plasma lipoprotein levels as predictors of cardiovascular death in women. Arch Intern Med 1993; 153 (19) 2209-2216 . Doi: 10.1001/archinte.1993.00410190045006
• 25 Brower M, Brennan K, Pall M, Azziz R. The severity of menstrual dysfunction as a predictor of insulin resistance in PCOS. J Clin Endocrinol Metab 2013; 98 (12) E1967-E1971 . Doi: 10.1210/jc.2013-2815
• 26 Dunaif A, Green G, Phelps RG, Lebwohl M, Futterweit W, Lewy L. Acanthosis Nigricans, insulin action, and hyperandrogenism: clinical, histological, and biochemical findings. J Clin Endocrinol Metab 1991; 73 (03) 590-595
• 27 Zahiri Z, Sharami SH, Milani F. , et al. Metabolic syndrome in patients with polycystic ovary syndrome in Iran. Int J Fertil Steril 2016; 9 (04) 490-496 . Doi: 10.22074/ijfs.2015.4607
• 28 Madani T, Hosseini R, Ramezanali F. , et al. Metabolic syndrome in infertile women with polycystic ovarian syndrome. Arch Endocrinol Metab 2016; 60 (03) 199-204 . Doi: 10.1590/2359-3997000000135
• 29 Malavazos AE, Cereda E, Ermetici F. , et al. The “lipid accumulation product” is associated with 2-hour postload glucose outcomes in overweight/obese subjects with nondiabetic fasting glucose. Int J Endocrinol 2015; 2015: 836941
• 30 Macut D, Božić Antić I, Bjekić-Macut J. , et al. Lipid accumulation product is associated with metabolic syndrome in women with polycystic ovary syndrome. Hormones (Athens) 2016; 15 (01) 35-44 . Doi: 10.14310/horm.2002.1592
• 31 Nascimento JX, Chein MB, de Sousa RM, Ferreira AdosS, Navarro PA, Brito LM. Importance of lipid accumulation product index as a marker of CVD risk in PCOS women. Lipids Health Dis 2015; 14: 62 . Doi: 10.1186/s12944-015-0061-y
• 32 Dewailly D, Lujan ME, Carmina E. , et al. Definition and significance of polycystic ovarian morphology: a task force report from the Androgen Excess and Polycystic Ovary Syndrome Society. Hum Reprod Update 2014; 20 (03) 334-352 . Doi: 10.1093/humupd/dmt061
• 33 Legro RS, Arslanian SA, Ehrmann DA. , et al; Endocrine Society. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2013; 98 (12) 4565-4592 . Doi: 10.1210/jc.2013-2350
• 34 Otten J, Ahrén B, Olsson T. Surrogate measures of insulin sensitivity vs the hyperinsulinaemic-euglycaemic clamp: a meta-analysis. Diabetologia 2014; 57 (09) 1781-1788
• 35 Schmidt J, Landin-Wilhelmsen K, Brännström M, Dahlgren E. Cardiovascular disease and risk factors in PCOS women of postmenopausal age: a 21-year controlled follow-up study. J Clin Endocrinol Metab 2011; 96 (12) 3794-3803 . Doi: 10.1210/jc.2011-1677
• 36 Zhao L, Zhu Z, Lou H. , et al. Polycystic ovary syndrome (PCOS) and the risk of coronary heart disease (CHD): a meta-analysis. Oncotarget 2016; 7 (23) 33715-33721 . Doi: 10.18632/oncotarget.9553